H.R. 1266: Combating Illicit Xylazine Act
H.R. 1266 status: Introduced.
What this bill does
Overall score
Bill summary
No official summary is available for this bill yet.
Key analysis
Impact analysis
Environment
Benefits
- No direct environmental benefit identified
Risks
- No direct environmental risk identified
Economy
Benefits
- Facilitates and expedites manufacturer submissions for xylazine.
Risks
- Entities manufacturing xylazine are exempt from certain security standard capital expenditures.
Society
Benefits
- Adds xylazine to Schedule III of the Controlled Substances Act, increasing regulatory control.
- Clarifies 'ultimate user' definition for xylazine to include specific animal-related and government uses.
- Requires review and potential amendment of sentencing guidelines for xylazine offenses.
- Mandates reports to Congress on illicit xylazine use, diversion, and trafficking.
Risks
- Delays full implementation of Schedule III labeling, packaging, and distribution requirements for xylazine by one year.
- Delays full implementation of Schedule III practitioner registration, inventory, and recordkeeping for xylazine by 60 days.
How trustworthy & consequential it is
Confidence
highhigh
Information is complete and verified.
Analysis status
Full bill text (Congress.gov)
Source used for this bill's analysis.
The full impact depends on the effectiveness of the DEA and FDA in facilitating manufacturer submissions.
The bill does not prohibit all uses of xylazine, only certain illicit uses.
Where it stands
Introduced
CurrentIntroduced
Committee
UpcomingFloor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.